NO20014346L - Antibody and chemokine constructs targeting CCR5 and their use in the treatment of autoimmune diseases - Google Patents

Antibody and chemokine constructs targeting CCR5 and their use in the treatment of autoimmune diseases

Info

Publication number
NO20014346L
NO20014346L NO20014346A NO20014346A NO20014346L NO 20014346 L NO20014346 L NO 20014346L NO 20014346 A NO20014346 A NO 20014346A NO 20014346 A NO20014346 A NO 20014346A NO 20014346 L NO20014346 L NO 20014346L
Authority
NO
Norway
Prior art keywords
antibody
chemokine
autoimmune diseases
treatment
cells
Prior art date
Application number
NO20014346A
Other languages
Norwegian (no)
Other versions
NO316916B1 (en
NO20014346D0 (en
Inventor
Matthias Mack
Detlef Schloendorff
Hilke Bruehl
Original Assignee
Micromet Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromet Ag filed Critical Micromet Ag
Publication of NO20014346D0 publication Critical patent/NO20014346D0/en
Publication of NO20014346L publication Critical patent/NO20014346L/en
Publication of NO316916B1 publication Critical patent/NO316916B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Abstract

The invention relates to antibody and chemokine constructs against chemokine receptor expressing cells, especially against monocytes/macrophages expressing the chemokine receptor CCR5 and CCR5<+> T cells. The invention further relates to the use of antibody and chemokine constructs for destroying cells expressing the chemokine receptor for treating autoimmune diseases and allergic diseases, especially for treating chronic inflammatory diseases of the joints. The inventive antibody and chemokine constructs facilitate the specific depletion of chemokine receptor expressing cells and thus a specific immunosuppressive therapy of autoimmune diseases.
NO20014346A 1999-03-11 2001-09-06 Use of a bispecific antibody construct targeting CCR5 and CD3 for the preparation of a pharmaceutical composition for the treatment of chronic arthritis, autoimmune diseases, allergic reactions or for the reduction of chemokine receptor expression NO316916B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19910891 1999-03-11
PCT/EP2000/002154 WO2000053633A2 (en) 1999-03-11 2000-03-10 Antibody and chemokine constructs that are directed to ccr5, and their use for treating autoimmune diseases

Publications (3)

Publication Number Publication Date
NO20014346D0 NO20014346D0 (en) 2001-09-06
NO20014346L true NO20014346L (en) 2001-09-27
NO316916B1 NO316916B1 (en) 2004-06-21

Family

ID=7900625

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014346A NO316916B1 (en) 1999-03-11 2001-09-06 Use of a bispecific antibody construct targeting CCR5 and CD3 for the preparation of a pharmaceutical composition for the treatment of chronic arthritis, autoimmune diseases, allergic reactions or for the reduction of chemokine receptor expression

Country Status (15)

Country Link
EP (1) EP1161456B1 (en)
JP (1) JP2002540771A (en)
CN (1) CN1345336A (en)
AT (1) ATE286074T1 (en)
AU (1) AU4104700A (en)
CA (1) CA2366713A1 (en)
CZ (1) CZ20013270A3 (en)
DE (1) DE50009113D1 (en)
ES (1) ES2233359T3 (en)
HU (1) HUP0200484A2 (en)
IL (1) IL145335A0 (en)
NO (1) NO316916B1 (en)
SK (1) SK12782001A3 (en)
TR (1) TR200102779T2 (en)
WO (1) WO2000053633A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528625B1 (en) 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same
JP2004508036A (en) * 2000-09-08 2004-03-18 マイクロメット　アーゲー Antibodies and / or chemokine constructs and their use in immune disorders
EP1456241B1 (en) * 2001-12-21 2005-03-16 Micromet AG Mono-and dual anti-cd4-rantes chemokine/cytokine constructs
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
AU2007286451A1 (en) 2006-08-17 2008-02-21 F. Hoffmann-La Roche Ag A conjugate of an antibody against CCR5 and an antifusogenic peptide
BRPI0717512A2 (en) 2006-09-29 2013-11-19 Hoffmann La Roche CCR5 ANTIBODIES AND USES OF THE SAME
US20090143288A1 (en) 2007-03-13 2009-06-04 Roche Palo Alto Llc Peptide-complement conjugates
BR112013013311A2 (en) 2010-11-30 2017-09-19 Chugai Pharmaceutical Co Ltd cytotoxicity-inducing therapeutic agent
EP2741777B1 (en) 2011-08-12 2017-01-18 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for treatment of pulmonary hypertension
TWI726842B (en) 2014-04-07 2021-05-11 日商中外製藥股份有限公司 Immune activation antigen binding molecule
MX2016014434A (en) * 2014-05-13 2017-02-23 Chugai Pharmaceutical Co Ltd T cell-redirected antigen-binding molecule for cells having immunosuppression function.
JP6931329B2 (en) 2015-11-18 2021-09-01 中外製薬株式会社 Combination therapy using T cell redirection antigen-binding molecule for cells with immunosuppressive function
JP6925278B2 (en) 2015-11-18 2021-08-25 中外製薬株式会社 Method of enhancing humoral immune response

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6428788B1 (en) * 1995-03-15 2002-08-06 Penn State University Compositions and methods for specifically targeting tumors
US6528625B1 (en) * 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same
ZA985542B (en) * 1997-07-03 1999-04-07 Smithkline Beecham Corp Substituted benzanilides as CCR5 receptor ligands antiinflammatory agents and antiviral agents
EP1346731B1 (en) * 1998-07-22 2006-12-06 Osprey Pharmaceuticals Limited Conjugates for treating inflammatory disorders and associated tissue damage

Also Published As

Publication number Publication date
AU4104700A (en) 2000-09-28
TR200102779T2 (en) 2002-03-21
WO2000053633A2 (en) 2000-09-14
CN1345336A (en) 2002-04-17
JP2002540771A (en) 2002-12-03
DE50009113D1 (en) 2005-02-03
IL145335A0 (en) 2002-06-30
EP1161456B1 (en) 2004-12-29
EP1161456A2 (en) 2001-12-12
CA2366713A1 (en) 2000-09-14
NO316916B1 (en) 2004-06-21
SK12782001A3 (en) 2002-03-05
HUP0200484A2 (en) 2002-06-29
NO20014346D0 (en) 2001-09-06
ES2233359T3 (en) 2005-06-16
ATE286074T1 (en) 2005-01-15
WO2000053633A3 (en) 2000-11-16
CZ20013270A3 (en) 2002-02-13

Similar Documents

Publication Publication Date Title
NO20014346D0 (en) Antibody and chemokine constructs targeting CCR5 and their use in the treatment of autoimmune diseases
CY1120070T1 (en) METHOD OF THERAPEUTIC TREATMENT WITH THE USE OF ANTI-ERBB-METHYSINEOID ANTIBODY conjugates
EP1470146B8 (en) Antibodies against the muc18 antigen
CR7875A (en) IMMUNOGLOBIN VARIANTS AND USES OF THIS
NZ593428A (en) Therapeutic human anti-il-1r1 monoclonal antibody
EP2267032A3 (en) Method of administering therapeutic polypeptides, and polypeptides therefor
PT1641483E (en) Fusion proteins
DE60333121D1 (en) PERS 14.18 BINDING GD2 AND ITS FUSION WITH IL-2
PL373567A1 (en) Conjugates of therapeutic or cytotoxic agents and biologically active peptides
EP1389209A4 (en) Folate mimetics and folate-receptor binding conjugates thereof
ATE473011T1 (en) MODIFIED TRANSFERRIN FUSION PROTEINS WITH DOUBLE TRANSFERRIN-AMINO OR CARBOXY TERMINAL DOMAIN
EP2298811A3 (en) Human anti-ifn-gamma neutralizing antibodies as selective ifn-gamma pathway inhibitors
PT1137436E (en) Stimulation of t-cells against self antigens using ctla-4 blocking agents
TR200000913T2 (en) Medical substances
BR9805012A (en) hyperuricemia in a mammal suffering from hyperuricema.
AU7226301A (en) Pyridoxine and pyridoxal analogues: cardiovascular therapeutics
WO1998009642A3 (en) Therapeutic chemokine antagonists
AU2001234273A1 (en) Thiazolopyrimidines and their use as modulators of chemokine receptor activity
MY137620A (en) Therapeutic treatment
WO2004032850A3 (en) Uses of human zven antagonists
ATE291586T1 (en) HUMAN ANTIBIOTIC PROTEIN
GB0102145D0 (en) Substances
ES2013321A6 (en) Monoclonal antibodies to Pseudomonas aeruginosaflagella
DK1196188T3 (en) VGF-selective monoclonal antibodies and their use in the treatment of VGF-related disorders
AU2002229850A1 (en) Polypeptide inducing hiv-neutralising antibodies